Hormone therapies that suppress systemic androgen production (e.g., abiraterone) or block testosterone from binding to the androgen receptor (e.g., enzalutamide) are used to treat CRPC and have caused an increase in the percentage of metastatic CRPC patients who have AR-negative cancer (from 11% to 36%) [4,6,7]. This evidence concerns the gene AR and cancer.